Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variants
Lv, H.; Feng, Z.; Teo, Q. W.; Chen, C.; Gopal, A. B.; Choi, D.; Tan, T. J. C.; Tang, Y. S.; Siu, L.; Nourmohammad, A.; Bruzzone, R.; Wilson, I. A.; Yuan, M.; Wu, N. C.; Mok, C. K.-P.
Show abstract
Rapid antigenic drift of the SARS-CoV-2 receptor-binding domain (RBD) underlies immune escape and continues to challenge the durability of antibody-mediated protection. Among the major classes of RBD-directed antibodies, germline-encoded IGHV3-53 responses are highly potent against early SARS-CoV-2 variants but are generally compromised by Omicron-associated mutations. Here, we identify an intrinsically cross-reactive IGHV3-53 germline antibody that recognizes multiple pre-Omicron variants, including SARS-CoV-2 wild-type, Alpha, and Delta. Notably, we demonstrate that targeted somatic evolution can further expand this breadth to overcome the immune escape of different Omicron variants. Guided by integrated structural and sequence analyses, we introduce four somatic mutations (G26E, T28I, S53P, and Y58F) into the germline antibody, resulting in markedly enhanced binding and neutralization of Omicron BA.1, BA.2, and BA.4/5. High-resolution crystal structures reveal that these mutations re-establish critical interactions disrupted by substitutions on Omicron RBD and optimize affinity at a remodeled epitope interface. Collectively, our findings delineate a structural and mechanistic pathway through which an inherently cross-reactive germline antibody lineage can be adaptively refined to counter highly divergent SARS-CoV-2 variants. This work highlights the underappreciated breadth encoded within the naive B-cell repertoire and provides a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift 98%
- Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design 97%
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination 97%
Similar papers in this journal
- A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo 97%
- Characterization of two non-competing antibodies to influenza H3N2 hemagglutinin stem reveals its evolving antigenicity 97%
- Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain 97%
Similar papers in this journal
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses 97%
- Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 97%
- Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding 97%
Similar papers in this journal
- Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies 97%
- Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response 96%
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.